Diagnostic Imaging’s Weekly Scan: July 26 — August 1

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

In comparison to findings from a similar study in 2014, the national volume computed tomography (CT) dose index (CTDLvol) declined by 9.3 percent, according to newly published research involving 5 million CT exams for over 2.8 million adults in 2025. The researchers also pointed out a 21.8 percent decrease in diagnostic reference levels (DRLs) for CT exams between 2014 and 2025.

The Food and Drug Administration (FDA) has issued an expanded approval of lutetium LU 177 vipivotide tetraxetan (Pluvicto, Novartis). Pluvicto may now be utilized in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of PSMA-positive metastatic androgen pathway modulation-naïve/sensitive (mAPMN/S) prostate cancer (PCa).The expanded approval, based on results from the phase III PSMAddition trial, may nearly double the number of patients with prostate cancer who can be treated with Pluvicto.

In an external test set from a recent study, a combined radiomic/deep learning model for intratumoral computed tomography (CT) threshold segmentation offered an 82.3 percent AUC and 95.4 percent sensitivity for predicting visceral pleural invasion in patients with lung adenocarcinoma < 30 mm.

The Food and Drug Administration (FDA) has granted a De Novo classification for the AI-enabled CaRi-Heart software, which enables quantification of coronary inflammation that may signal elevated cardiovascular risks, even in patients with low or zero coronary artery calcium (CAC) scoring.

Findings from a new comparative study demonstrate that biparametric magnetic resonance imaging (bpMRI) may provide comparable detection to multiparametric MRI (mpMRI) for assessing extraprostatic extension (EPE) in patients with prostate cancer (PCa).